Dare Bioscience DARE

NASDAQ DARE

$0.72 +0.00 (+0.50%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap10.67 Mn

P/E-0.89

P/S8.95

Div. Yield0.00

Revenue Growth (1y) (Qtr)985.82

Add ratio to table…

About

Dare Bioscience Inc is a biopharmaceutical company dedicated to advancing women's health through the development and commercialization of evidence based solutions. The firm concentrates on acquiring or in licensing intellectual property that enables it to create product candidates targeting unmet medical needs in contraception female sexual dysfunction menopausal hormone therapy and bacterial vaginosis. By pursuing multiple regulatory pathways including seeking FDA approval for prescription drugs utilizing Section 503B compounding for certain formulations and offering consumer health products that do not require a prescription Dare Bioscience aims to bring innovations to patients quickly and efficiently. The company's pipeline includes both late stage clinical programs such as the pivotal Phase 3 study of Ovaprene a hormone free monthly intravaginal contraceptive and earlier stage projects like DARE to PLAY a topical sildenafil cream for female sexual arousal disorder. Dare Bioscience also leverages non dilutive funding from government grants and foundations to support research and development activities. This integrated strategy allows the firm to balance scientific advancement with financial discipline while addressing significant gaps in women's healthcare.

Currently Dare Bioscience derives most of its revenue from royalty and milestone payments associated with its licensing agreement with Organon for the approved product XACIATO which treats bacterial vaginosis. These payments reflect net sales of XACIATO and the achievement of predetermined commercial and regulatory milestones set forth in the agreement. In addition the company expects to generate future income from its Section 503B compounding portfolio which includes DARE to PLAY a topical sildenafil cream intended for female sexual arousal disorder and DARE to RECLAIM an estradiol progesterone intravaginal ring designed for menopausal symptom relief. Dare Bioscience also plans to commercialize its consumer health line DARE to RESTORE consisting of vaginal probiotic suppositories that are sold without a prescription and marketed directly to consumers and healthcare providers. The firm continues to pursue non dilutive funding sources such as federal grants foundation awards and other non equity financing to offset research and development expenses. Looking ahead Dare Bioscience may explore additional licensing collaborations or out licensing arrangements that could produce upstream royalty streams or milestone payments from partners seeking to develop its earlier stage assets.

Dare Bioscience operates within the competitive women's health sector where it faces rivalry from large established pharmaceutical companies as well as agile biotech specialists focusing on niche indications. Major competitors include Organon which now markets XACIATO Bayer which has a history in contraceptive devices and various firms that sell hormonal and non hormonal therapies for menopause and sexual health. The company distinguishes itself through its proprietary formulations that have been evaluated in clinical studies its willingness to use alternative regulatory routes such as Section 503B compounding and the 505 b 2 pathway and its network of manufacturing and distribution partners. These attributes allow Dare Bioscience to bring novel products to market without the need to build costly internal sales and distribution infrastructures. Furthermore the firm's emphasis on evidence based solutions and its ability to leverage existing safety data for active ingredients supports its efforts to achieve regulatory approval and market acceptance. By maintaining a capital efficient model and concentrating on high unmet need areas Dare Bioscience seeks to carve out a sustainable position in the women's health marketplace.

The ultimate customers of Dare Bioscience are women patients who obtain its products through prescribers pharmacies or retail channels depending on the product type. For its FDA approved product XACIATO the company relies on Organon as the exclusive licensee responsible for manufacturing distribution and commercialization worldwide. In the Section 503B compounding arena Dare Bioscience works with Bravado Pharmaceuticals which manufactures DARE to PLAY and Medvantx which operates the DARE Health Hub processes prescriptions and handles payment processing for patients. The consumer health line DARE to RESTORE is produced by Probiotical which supplies the vaginal probiotic suppositories and collaborates with Dare Bioscience on marketing and distribution efforts. Additionally the firm engages telehealth platforms and outsourcing facilities to support the prescribing and dispensing of its compounded drugs ensuring that patients can access therapy through virtual consultations and home delivery. These relationships enable Dare Bioscience to reach its target audience while relying on external partners for scale and operational expertise.

Investment Thesis

▲ Bull case

Dare Bioscience is positioned to capture significant market share in the female sexual arousal market through its DARE to PLAY sildenafil cream, which is the only product with clinical data demonstrating increased genital blood flow within 10 to 15 minutes of application in women, validated by FDA-reviewed endpoints. Unlike compounded alternatives from 503A pharmacies that lack female-specific clinical validation, DARE to PLAY's GMP manufacturing ensures consistent potency and quality, addressing a critical unmet need for the estimated 20 million U.S. women reporting arousal challenges. The pre-fulfillment prescribing model already active across all 50 states via telehealth and brick-and-mortar providers is building clinician relationships and patient demand ahead of national dispensing, creating a first-mover advantage in a market with no FDA-approved therapies. This dual-path strategy—generating real-world prescribing data through 503B compounding while advancing toward FDA approval via the 505(b)(2) NDA pathway—allows Dare to monetize early adoption while strengthening regulatory submissions, a structural advantage not replicated by competitors relying solely on traditional development or compounding models. The company's ability to leverage its clinical data and formulation differentiation (DermaFlux technology) to educate providers and consumers on rapid onset of action creates a defensible moat against generic compounded alternatives, as clinicians and patients increasingly prioritize products with proven female-specific efficacy and safety profiles. With revenue expected to begin in Q2 2026 and scalable digital-native commercialization through the DARE Health Hub, Dare is establishing a capital-efficient platform for long-term growth in women's sexual health, a sector experiencing historic increases in payer, provider, and political attention that Dare has anticipated through a decade of focused pipeline development.
Beyond DARE to PLAY, Dare Bioscience's pipeline contains multiple near-term catalysts with substantial undervalued potential, beginning with DARE to RESTORE's Flora Sync LF5 vaginal probiotic suppository, which is expected to launch commercially in Q2 2026 based on a 100-person human clinical trial published in a peer-reviewed journal using Probiotical's proprietary LF5 strain. This level of clinical evidence distinguishes it from the majority of vaginal probiotics on the market that lack human trial data, creating a credible differentiator in a growing consumer health segment focused on microbiome balance. The product will be distributed through the existing DARE Health Hub, leveraging the same telehealth and digital marketing infrastructure as DARE to PLAY, enabling cross-selling opportunities and reduced customer acquisition costs. Simultaneously, Ovaprene—the company's monthly intravaginal hormone-free contraceptive—is advancing in a Phase III pivotal trial with enrollment expected to complete in 2026, positioning a 2027 data readout for what could be the first non-implanted, non-hormonal monthly contraceptive option in a market where younger women are actively seeking alternatives to hormonal methods. This addresses a clear gap in contraceptive options beyond condoms and vaginal gels, with partnership and licensing potential that the market has dramatically undervalued given the global shift toward non-hormonal solutions. Furthermore, DARE-HPV, which received FDA IND clearance in February 2026 and is advancing into a Phase II study later in 2026 with ARPA-H funding, targets the completely untreated population of approximately 6 million U.S. women annually acquiring high-risk HPV infections—a pharmacologic market with zero existing drug therapies and a direct link to preventing cervical cancer (99% of cases stem from high-risk HPV). The combination of significant non-dilutive funding across these programs (including Gates Foundation, ARPA-H, and NIH grants) reduces shareholder dilution while de-risking development, allowing Dare to advance multiple high-potential assets in parallel. This portfolio approach creates a catalyst stack where near-term revenue from DARE to PLAY and DARE to RESTORE in Q2 2026 funds ongoing development, while mid-term milestones like Ovaprene's 2027 data readout and DARE-HPV's Phase II results offer multiple pathways to re-rating as investors recognize the breadth and clinical validation of Dare's women's health-exclusive pipeline.

Dare Bioscience is positioned to capture significant market share in the female sexual arousal market through its DARE to PLAY sildenafil cream, which is the only product with clinical data demonstrating increased genital blood flow within 10 to 15 minutes of application in women, validated by FDA-reviewed endpoints. Unlike compounded alternatives from 503A pharmacies that lack female-specific clinical validation, DARE to PLAY's GMP manufacturing ensures consistent potency and quality, addressing a critical unmet need for the estimated 20 million U.S. women reporting arousal challenges. The pre-fulfillment prescribing model already active across all 50 states via telehealth and brick-and-mortar providers is building clinician relationships and patient demand ahead of national dispensing, creating a first-mover advantage in a market with no FDA-approved therapies. This dual-path strategy—generating real-world prescribing data through 503B compounding while advancing toward FDA approval via the 505(b)(2) NDA pathway—allows Dare to monetize early adoption while strengthening regulatory submissions, a structural advantage not replicated by competitors relying solely on traditional development or compounding models. The company's ability to leverage its clinical data and formulation differentiation (DermaFlux technology) to educate providers and consumers on rapid onset of action creates a defensible moat against generic compounded alternatives, as clinicians and patients increasingly prioritize products with proven female-specific efficacy and safety profiles. With revenue expected to begin in Q2 2026 and scalable digital-native commercialization through the DARE Health Hub, Dare is establishing a capital-efficient platform for long-term growth in women's sexual health, a sector experiencing historic increases in payer, provider, and political attention that Dare has anticipated through a decade of focused pipeline development.
Beyond DARE to PLAY, Dare Bioscience's pipeline contains multiple near-term catalysts with substantial undervalued potential, beginning with DARE to RESTORE's Flora Sync LF5 vaginal probiotic suppository, which is expected to launch commercially in Q2 2026 based on a 100-person human clinical trial published in a peer-reviewed journal using Probiotical's proprietary LF5 strain. This level of clinical evidence distinguishes it from the majority of vaginal probiotics on the market that lack human trial data, creating a credible differentiator in a growing consumer health segment focused on microbiome balance. The product will be distributed through the existing DARE Health Hub, leveraging the same telehealth and digital marketing infrastructure as DARE to PLAY, enabling cross-selling opportunities and reduced customer acquisition costs. Simultaneously, Ovaprene—the company's monthly intravaginal hormone-free contraceptive—is advancing in a Phase III pivotal trial with enrollment expected to complete in 2026, positioning a 2027 data readout for what could be the first non-implanted, non-hormonal monthly contraceptive option in a market where younger women are actively seeking alternatives to hormonal methods. This addresses a clear gap in contraceptive options beyond condoms and vaginal gels, with partnership and licensing potential that the market has dramatically undervalued given the global shift toward non-hormonal solutions. Furthermore, DARE-HPV, which received FDA IND clearance in February 2026 and is advancing into a Phase II study later in 2026 with ARPA-H funding, targets the completely untreated population of approximately 6 million U.S. women annually acquiring high-risk HPV infections—a pharmacologic market with zero existing drug therapies and a direct link to preventing cervical cancer (99% of cases stem from high-risk HPV). The combination of significant non-dilutive funding across these programs (including Gates Foundation, ARPA-H, and NIH grants) reduces shareholder dilution while de-risking development, allowing Dare to advance multiple high-potential assets in parallel. This portfolio approach creates a catalyst stack where near-term revenue from DARE to PLAY and DARE to RESTORE in Q2 2026 funds ongoing development, while mid-term milestones like Ovaprene's 2027 data readout and DARE-HPV's Phase II results offer multiple pathways to re-rating as investors recognize the breadth and clinical validation of Dare's women's health-exclusive pipeline.

▼ Bear case

Dare Bioscience faces significant execution risks in commercializing DARE to PLAY, as the company remains in a pre-fulfillment phase with no actual dispensing or revenue generated to date, despite prescribing activity beginning in February 2026 across all 50 states. The reliance on telehealth and brick-and-mortar providers to write prescriptions without guaranteed conversion to dispensed orders introduces uncertainty about real patient demand, particularly given that women may opt for immediately available compounded sildenafil creams from 503A pharmacies rather than wait for DARE to PLAY's national rollout. The company's assumption that clinicians and patients will prefer its product due to faster onset (10–15 minutes) and GMP quality overlooks potential barriers such as lack of insurance coverage for a non-FDA-approved compounded product, higher out-of-pocket costs compared to generic alternatives, and entrenched prescribing habits favoring established oral therapies like Viagra for off-label use in women. Furthermore, while Dare emphasizes its DermaFlux technology and clinical data on blood flow increase, it has not disclosed whether the arousal, orgasm, and desire endpoints used in its studies will meet FDA's satisfaction for a 505(b)(2) NDA, and the ongoing dialogue with the FDA about co-primary assessment components—particularly interpersonal challenges—suggests potential delays or additional trial requirements that could push approval beyond management's implied timeline. The commercial model's dependence on digital marketing and telehealth partnerships also carries customer acquisition cost risks, as Dare has not provided data on conversion rates from prescription to dispensing or patient retention, leaving unanswered questions about the scalability and profitability of its direct-to-consumer approach in a crowded women's health digital space.
Dare Bioscience's pipeline advancement is heavily contingent on continued non-dilutive grant funding, which, while reducing shareholder dilution, creates vulnerability if key awards from the Gates Foundation, ARPA-H, or NIH are not renewed or expanded beyond current levels. The company disclosed that its reported R&D expenses ($5.5 million in 2025) are significantly offset by contra R&D expense from grants ($13.9 million), meaning its actual R&D investment is substantially higher than the income statement suggests; a reduction in grant funding would force difficult choices between cutting programs or increasing shareholder-dilutive financing. Programs like DARE to RECLAIM, targeting the $2.5–$4.5 billion bioidentical hormone therapy market with a 2027 503B commercial target, and DARE-HPV, advancing into Phase II with ARPA-H support, remain early-stage and lack near-term revenue visibility, increasing the risk that investor enthusiasm for the pipeline outpaces near-term financial performance. Additionally, Ovaprene's Phase III trial, while progressing toward enrollment completion in 2026, has not released any efficacy or safety data since the Data Safety Monitoring Board's July 2025 recommendation to continue without modification, leaving uncertainty about whether the trial will meet its primary endpoints for a PMA submission. The company's strategy of pursuing dual paths (503B commercialization alongside regulatory approval) for multiple products may dilute focus and resources, particularly as it attempts to build market awareness for DARE to PLAY while simultaneously preparing regulatory files—a strategy that could strain limited operational capacity given Dare's small size and historical reliance on external partners for manufacturing (e.g., Probiotical for Flora Sync LF5) and fulfillment (Medvantx). Finally, despite management's emphasis on a decade-long buildup in women's health, the company has yet to demonstrate sustainable profitability or positive cash flow from operations, with its $24.7 million cash balance as of December 2025 dependent on recent equity raises ($20.8 million in net proceeds from ATM sales in 2025) rather than internal cash generation, raising concerns about its ability to fund operations and commercial expansion without further dilution if near-term revenue from DARE to PLAY and DARE to RESTORE fails to meet expectations.

Dare Bioscience faces significant execution risks in commercializing DARE to PLAY, as the company remains in a pre-fulfillment phase with no actual dispensing or revenue generated to date, despite prescribing activity beginning in February 2026 across all 50 states. The reliance on telehealth and brick-and-mortar providers to write prescriptions without guaranteed conversion to dispensed orders introduces uncertainty about real patient demand, particularly given that women may opt for immediately available compounded sildenafil creams from 503A pharmacies rather than wait for DARE to PLAY's national rollout. The company's assumption that clinicians and patients will prefer its product due to faster onset (10–15 minutes) and GMP quality overlooks potential barriers such as lack of insurance coverage for a non-FDA-approved compounded product, higher out-of-pocket costs compared to generic alternatives, and entrenched prescribing habits favoring established oral therapies like Viagra for off-label use in women. Furthermore, while Dare emphasizes its DermaFlux technology and clinical data on blood flow increase, it has not disclosed whether the arousal, orgasm, and desire endpoints used in its studies will meet FDA's satisfaction for a 505(b)(2) NDA, and the ongoing dialogue with the FDA about co-primary assessment components—particularly interpersonal challenges—suggests potential delays or additional trial requirements that could push approval beyond management's implied timeline. The commercial model's dependence on digital marketing and telehealth partnerships also carries customer acquisition cost risks, as Dare has not provided data on conversion rates from prescription to dispensing or patient retention, leaving unanswered questions about the scalability and profitability of its direct-to-consumer approach in a crowded women's health digital space.
Dare Bioscience's pipeline advancement is heavily contingent on continued non-dilutive grant funding, which, while reducing shareholder dilution, creates vulnerability if key awards from the Gates Foundation, ARPA-H, or NIH are not renewed or expanded beyond current levels. The company disclosed that its reported R&D expenses ($5.5 million in 2025) are significantly offset by contra R&D expense from grants ($13.9 million), meaning its actual R&D investment is substantially higher than the income statement suggests; a reduction in grant funding would force difficult choices between cutting programs or increasing shareholder-dilutive financing. Programs like DARE to RECLAIM, targeting the $2.5–$4.5 billion bioidentical hormone therapy market with a 2027 503B commercial target, and DARE-HPV, advancing into Phase II with ARPA-H support, remain early-stage and lack near-term revenue visibility, increasing the risk that investor enthusiasm for the pipeline outpaces near-term financial performance. Additionally, Ovaprene's Phase III trial, while progressing toward enrollment completion in 2026, has not released any efficacy or safety data since the Data Safety Monitoring Board's July 2025 recommendation to continue without modification, leaving uncertainty about whether the trial will meet its primary endpoints for a PMA submission. The company's strategy of pursuing dual paths (503B commercialization alongside regulatory approval) for multiple products may dilute focus and resources, particularly as it attempts to build market awareness for DARE to PLAY while simultaneously preparing regulatory files—a strategy that could strain limited operational capacity given Dare's small size and historical reliance on external partners for manufacturing (e.g., Probiotical for Flora Sync LF5) and fulfillment (Medvantx). Finally, despite management's emphasis on a decade-long buildup in women's health, the company has yet to demonstrate sustainable profitability or positive cash flow from operations, with its $24.7 million cash balance as of December 2025 dependent on recent equity raises ($20.8 million in net proceeds from ATM sales in 2025) rather than internal cash generation, raising concerns about its ability to fund operations and commercial expansion without further dilution if near-term revenue from DARE to PLAY and DARE to RESTORE fails to meet expectations.

Statement Business Segments Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

Dare Bioscience DARE

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Statement Business Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password